A Randomized Phase II Trial of Atezolizumab with or without Bevacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer

Brief description of study

If you have been diagnosed with urothelial or transitional cell cancer that cannot be operated on or has spread and you are not a candidate for cisplatin chemotherapy, you may qualify for this study. Atezolizumab is a standard treatment for patients who are not candidates for cisplatin and the main goal of this phase II study is to test whether adding bevacizumab to atezolizumab improves outcomes compared to atezolizumab alone.

Clinical Study Identifier: s16-01918
ClinicalTrials.gov Identifier: NCT03272217
Principal Investigator: Arjun Vasant Balar.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.